BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies…
View this webinar to learn about the many exciting opportunities available at the 2023 BIO Asia-Taiwan International Conference & Exhibition. This webinar covers:
- Overview of the event schedule
- Preview of conference sessions and programming
- Live demo of the BIO One-on-One Partnering…
Ending the week with a win—actually three, as Congress introduced three important bills drafted with BIO support. And as National Pollinator Week comes to a close, we explore how biotech is giving a boost to bees. (678 words, 3 minutes, 23 seconds)
A busy news day: USDA approves cultivated meat, House members talk PBM transparency, and CDC advisers recommend RSV shots for people over 60, among other headlines. (694 words, 3 minutes, 28 seconds)
Today, a look at a new working group to drive harmonization of cell and gene therapies worldwide (which BIO supports) and what one member of Congress said about the Inflation Reduction Act and orphan drugs. (682 words, 3 minutes, 24 seconds)
BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies…
The Paris Air Show puts a spotlight on SAF, and World Sickle Cell Day (yesterday) highlights the importance of advancing new treatments—which could be here soon. (571 words, 2 minutes, 51 seconds)
The House Ways & Means Committee takes a welcome first step on R&D amortization—plus, we explore how the biopharma industry is reducing emissions and improving sustainable practices. (521 words, 2 minutes, 36 seconds)
Hospitals in the 340B Program are exploiting lax eligibility criteria and program guardrails to profit from the substantial 340B discounts that were intended to ensure low-income access to discounted prescription drugs and services. Despite the intent of the program, the 340B statute does not…